Literature DB >> 12099579

Peroxisome proliferator-activated receptor gamma (PPargamma) as a novel target for prostate cancer.

Matthew R Smith1, Philip W Kantoff.   

Abstract

Peroxisome proliferator activated receptor-gamma (PPARgamma) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. PPARgamma is expressed at high levels in adipose tissue and plays a central role in adipocyte differentiation. Recent studies have implicated PPARgamma in the pathogenesis of several human malignancies. Here we review the evidence that PPARgamma contributes to prostate carcinogenesis and the potential for PPARgamma as a novel therapeutic target for prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12099579     DOI： 10.1023/a:1015670126203

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  27 in total

Review 1.  Roles of PPARs in health and disease.

Authors:  S Kersten; B Desvergne; W Wahli
Journal:  Nature       Date:  2000-05-25       Impact factor: 49.962

2.  PPARgamma and colorectal carcinoma: conflicts in a nuclear family.

Authors:  B Seed
Journal:  Nat Med       Date:  1998-09       Impact factor: 53.440

3.  A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans.

Authors:  A Meirhaeghe; L Fajas; N Helbecque; D Cottel; P Lebel; J Dallongeville; S Deeb; J Auwerx; P Amouyel
Journal:  Hum Mol Genet       Date:  1998-03       Impact factor: 6.150

4.  Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy.

Authors:  G L Rubin; Y Zhao; A M Kalus; E R Simpson
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

5.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authors:  G D Demetri; C D Fletcher; E Mueller; P Sarraf; R Naujoks; N Campbell; B M Spiegelman; S Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2.

Authors:  R Butler; S H Mitchell; D J Tindall; C Y Young
Journal:  Cell Growth Differ       Date:  2000-01

7.  Peroxisome proliferator-activated receptor gamma C161-->T polymorphism and coronary artery disease.

Authors:  X L Wang; J Oosterhof; N Duarte
Journal:  Cardiovasc Res       Date:  1999-12       Impact factor: 10.787

8.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

9.  15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

Authors:  B M Forman; P Tontonoz; J Chen; R P Brun; B M Spiegelman; R M Evans
Journal:  Cell       Date:  1995-12-01       Impact factor: 41.582

10.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo.

Authors:  T Kubota; K Koshizuka; E A Williamson; H Asou; J W Said; S Holden; I Miyoshi; H P Koeffler
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701
View more
  11 in total

Review 1.  PPARγ: a molecular link between systemic metabolic disease and benign prostate hyperplasia.

Authors:  Ming Jiang; Douglas W Strand; Omar E Franco; Peter E Clark; Simon W Hayward
Journal:  Differentiation       Date:  2011-06-08       Impact factor: 3.880

2.  The PPARγ ligand ciglitazone regulates androgen receptor activation differently in androgen-dependent versus androgen-independent human prostate cancer cells.

Authors:  Patrice E Moss; Besstina E Lyles; LaMonica V Stewart
Journal:  Exp Cell Res       Date:  2010-10-13       Impact factor: 3.905

3.  Functional annotation of novel lineage-specific genes using co-expression and promoter analysis.

Authors:  Charu G Kumar; Robin E Everts; Juan J Loor; Harris A Lewin
Journal:  BMC Genomics       Date:  2010-03-09       Impact factor: 3.969

4.  Pyrimidinyl-arylpropionic acid derivatives: viable resources in the development of new antineoplastic agents.

Authors:  Xishan Xiong; Li Wang; Yangliang Ye; Lili Fu; Minli Chen; Qingyi Wang; Moyan Liu; Jing Tang; Bing Dai; Jianhua Shen; Changlin Mei
Journal:  Invest New Drugs       Date:  2009-06-17       Impact factor: 3.850

5.  DH9, a novel PPARγ agonist suppresses the proliferation of ADPKD epithelial cells: An association with an inhibition of β-catenin signaling.

Authors:  Moyan Liu; Lili Fu; Chunyan Liu; Xishan Xiong; Xiang Gao; Min Xiao; Houan Cai; Huimin Hu; Xueqi Wang; Changlin Mei
Journal:  Invest New Drugs       Date:  2009-09-16       Impact factor: 3.850

Review 6.  Retinoids: novel immunomodulators and tumour-suppressive agents?

Authors:  M R Carratù; C Marasco; G Mangialardi; A Vacca
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

7.  Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375.

Authors:  Yan Liu; Yang Meng; Hongyan Li; Jing Li; Jianjiang Fu; Yue Liu; Xiao-Guang Chen
Journal:  Med Oncol       Date:  2006       Impact factor: 3.738

8.  A Role for the PPARgamma in Cancer Therapy.

Authors:  Moray J Campbell; Carsten Carlberg; H Phillip Koeffler
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Disruption of PPARgamma signaling results in mouse prostatic intraepithelial neoplasia involving active autophagy.

Authors:  M Jiang; S Fernandez; W G Jerome; Y He; X Yu; H Cai; B Boone; Y Yi; M A Magnuson; P Roy-Burman; R J Matusik; S B Shappell; S W Hayward
Journal:  Cell Death Differ       Date:  2009-10-16       Impact factor: 15.828

10.  Gamma (gamma) tocopherol upregulates peroxisome proliferator activated receptor (PPAR) gamma (gamma) expression in SW 480 human colon cancer cell lines.

Authors:  Sharon E Campbell; William L Stone; Sarah G Whaley; Min Qui; Koyamangalath Krishnan
Journal:  BMC Cancer       Date:  2003-10-01       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.